Фармакологическая блокада ангиотензиновых рецепторов в лечении артериальной гипертензии: от саралазина до сартанов

1. Basso N, Terragno NA. History about the discovery of renin-angiotensin system. Hypertension 2001; 38: 1246–9.
2. Braun-Menendez E, Fasciolo JC, Leloir LF, Munoz JM. The substance causing renal hypertension. J Physiol 1940; 98: 283–98.
3. Page IH, Helmer ОH. A crystalline pressor substance (angiotonin) resulting from the interaction between renin and renin activator. J Exp Med 1940; 71: 29–42.
4. Braun-Menéndez E, Page IH. Suggested revision of nomenclature: angiotensin. Science 1958; 127: 242.
5. Ferreira SH. A bradykinin-potentiating factor (BPF) present in venom of Bothrops jararaca. Br J Pharmacol 1965; 24: 163–9.
6. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977; 196 (4288): 441–4.
7. Pals DT, Masucci FD, Sipos F. A specific competitive antagonist of the vascular action of angiotensin II. Circ Res 1971; 29: 664–72.
8. Castellion AW, Fulton RW. Preclinical pharmacology of saralasin. Kidney Int 1979 (Suppl. 9): S11–S19.
9. Brunner HR, Laragh JH, Baer L et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286 (9): 441–9.
10. Gavras H, Gavras I, Brunner HR, Liang CS. Physiologic studies with saralasin in animals. Kidney Int 1979; (Suppl. 9): S20–S28.
11. Steiner RW, Blantz RC. Acute reversal by saralasin of multiple intrarenal effects of angiotensin II. Am J Physiol 1979; 237 (5): F386–F391.
12. Miller ED, Delaney TJ. Blood flow alteration induced by saralasin or sodium nitroprusside in rats. Anestesiology 1981; 54 (3): 199–203.
13. Delaney TJ, Miller ED. Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats. Anestesiology 1980; 52 (2): 154–6.
14. Anderson DF, Binder ND. Short-term saralasine blockade of renal hypertension in fetal lambs. J Physiol 1991; 433: 383–92.
15. Ribout C, Yamaguchi N, Godin D et al. Intracoronary administration of saralasin: effects on cardiac arrhythmias induced by ischemia and reperfusion in the anaesthetized dog. Cardiovasc Res 1992; 26 (10): 968–72.
16. Streeten DH, Anderson GH, Freiberg JM, Dalakos TG. Use of an angiotensin II antagonist (saralasin) in the recognition of «angiotensinogenic» hypertension. N Engl J Med 1975; 292 (13): 657–62.
17. Case DB, Wallace JM, Keim HJ et al. Usefulness and limitations of saralasin, a partial competetitive agonist of angiotensinogen II, for evaluating the renin and sodium factors in hypertensive patients. Am J Med 1976; 60 (6): 825–36.
18. Konrads A, Meurer KA, Hummerich W et al. Antihypertensive effects of captopril and saralasin in essential hypertension. Am J Cardiol 1982; 49 (6): 1558–60.
19. Huland H, Bause HW, Clausen C, Doehn N. The influence of an angiotensin II antagonist, saralasin, given before nephrectomy, on kidney function after transplantation. A contolled prospective study. Transplantation 1983; 36 (2): 139–42.
20. Symons JD, Stebbins CL. Effects of angiotensin II receptor blockade during exercise: comparison of losartan and saralasin. J Cardiovasc Pharmacol 1996; 28 (2): 223–31.
21. Ip SP, Tsang SW, Wong TP et al. Saralasin, a nonspecific angiotensin II receptor antagonist, attenuates oxidative stress and tissue injury in cerulein-induced acute pancreatitis. Pancreas 2003; 26 (3): 224–9.
22. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637–45.
23. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial – The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7.
24. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
25. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360 (9335): 752–60.
26. Dahlöf B, Devereux RB, Kjeldsen SE. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
27. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first-choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545–53.
28. Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev Cardiovasc Ther 2008; 6 (9): 1195–201.
29. Lindholm L, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertenstion study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–10.
30. Malmqvist K, Kahan T, Edner M, Bergfeldt L. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). Am J Cardiol 2002; 90 (10): 1107–12.
31. Mortsell D, Malmqvist K, Held C, Kahan T. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. J Intern Med 2007; 261 (5): 472–9.
32. Комитет экспертов Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Диагностика и лечение артериальной гипертонии. Российские рекомендации (3-й пересмотр). М., 2008.
33. Parving H-H, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8.
34. Persson F, Rossing P, Hovind P et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes 2006; 55 (12): 3550–5.
35. Llewelyn DE, Garcia-Puig J. How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive diabetics. J Renin Angiotensin Aldosterone Syst 2004; 5 (3): 141–5.
36. Rossing K, Christensen PK, Andersen S et al. Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study. Diabetes Care 2003; 26 (3): 569–74.
37. Andersen S, Brochner-Mortensen J, Parving HH. Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 2003; 26 (12): 3296–302.
38. Palmer AJ, Annemans L, Roze S et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 2004; 27 (8): 1897–903.
39. Macfarlane DP, Paterson KR, Fisher M. Cardiovascular drugs as antidiabetic agents: evidence for prevention of type 2 diabetes. Diabetes Obes Metab 2008; 10 (7): 533–44.
40. Ernsberger P, Koletsky RJ. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr Opin Pharmacol 2007; 7 (2): 140–5.
41. Чазова И.Е., Мычка В.Б. Метаболический синдром. М., 2004.
42. Мычка В.Б., Мамырбаева К.М., Масенко В.П. и др. Возможности антигипертензивной терапии ирбесартаном в коррекции инсулинорезистентности и нарушений мозгового кровотока у больных с метаболическим синдромом. Сons. Med. 2006; 8 (11): 25–30.
43. Kintscher U, Bramlage P, Paar WD et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007; 6: 12.
44. Clasen R, Schupp M, Foryst-Ludwig A et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46 (1): 137–43.
45. Di Filippo C, Lampa E, Tufariello E et al. Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats. Obes Res 2005; 13 (11): 1909–14.
46. Voigt JP, Bramlage P, Fink H. Hypophagic effect of the angiotensin AT(1) receptor antagonist irbesartan in rats. Eur J Pharmacol 2007; 535: 233–7.
47. De las Heras N, Martín-Fernández B, Miana M et al. The protective effect of irbesartan in rats fed a high fat diet is associated with modification of leptin-adiponectin imbalance. J Hypertens 2009; 27 (Suppl. 6): S37–S41.
48. Shimamura M, Nakagami H, Shimosato T et al. Irbesartan improves endothelial dysfunction, abnormal lipid profile, proteinuria and liver dysfunction in Zucker diabetic fatty rats independent of glucose and insulin levels. Exp Ther Med 2011; 2 (5): 957–61.
49. Jordan J, Boye SW, Breton SL et al. Antihypertensive treatment in patients with class 3 obesity. Ther Adv Endocrinol Metab 2012; 3 (3): 93–8.
50. Taguchi I, Toyoda S, Takano K et al. Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension. Hypertens Res 2013 Feb 21. doi: 10.1038/hr.2013.3. [Epub ahead of print]

В.В.Фомин*, А.А.Свистунов

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
*fomin_vic@mail.ru

________________________________________________

V.V.Fomin*, A.A.Svistunov 
*fomin_vic@mail.ru